Back to results
US 2025/0145706 A1Published application
Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
AssigneeSinabiosolution GmbH
InventorMarcus DÜHREN-VON MINDEN
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110). The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Claims20
An antibody having
- a heavy chain amino acid sequence as represented by SEQ ID NO:
- 1 and a light chain amino acid sequence of SEQ ID NO:
- 2, or
- a heavy chain amino acid sequence of SEQ ID NO:
- 11 and a light chain amino acid sequence of SEQ ID NO:
- 12;
- or
- comprising a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO:
- 15 and SEQ ID NO:
- 20 in any combination with a variable light chain having a sequence selected from the list of SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, and SEQ ID NO:
- 19.
11 more elements
Dependencies are inferred from the claim text.